Characteristics | N = 121 |
---|---|
Trial location | |
 Sub-Saharan countries only | 104 (85.9) |
  • South Africa | 20 (19.2) |
  • Nigeria | 12 (11.5) |
  • Tanzania | 10 (9.6) |
  • Kenya | 8 (7.6) |
  • Uganda | 8 (7.6) |
  • Malawi | 6 (5.7) |
  • Rwanda | 4 (3.8) |
  • Ethiopia | 3 (2.8) |
 Several Sub-Saharan countries | 5 (4.1) |
 Sub-Saharan African countries and high-income countries (HICs) or other countries (not HICs) | 12 (8.9) |
Medical area | |
 Malaria | 25 (20.6) |
 HIV/AIDS | 24 (19.9) |
 Tuberculosis | 4 (3.3) |
 Diarrheal diseases | 3 (2.4) |
 Preterm birth complications | 2 (1.6) |
 Other diseases | 63 (52.2) |
Study design | |
 Parallel groups | 97 (80.1) |
 Clusters | 19 (15.8) |
 Factorial design | 3 (2.4) |
 Cross-over | 2 (1.7) |
Experimental intervention | |
 Pharmacological (drugs and nutritional supplements) | 74 (61.1) |
 Nonpharmacological | 47 (38.9) |
  • Participative interventions | 40 (85.1) |
  • Devices | 3 (6.3) |
  • Surgical procedures | 1 (2.3) |
  • Therapeutic strategies | 3 (6.3) |
Comparator | |
 Active treatment | 43 (35.5) |
 Usual care | 32 (26.4) |
 Placebo | 24 (19.9) |
 Other | 22 (18.2) |
Sample size (median [IQR]) | 346 [160–932] |